【作者】 杨波； 黎海莉； 吴小华； 张立芳；

【Author】 Yang Bo Li Hai-Li Wu Xiao-Hua Zhang Li-Fang Department of Obsterics and Gynecology, the fourth hospital of Hebei medical university & Hebei provincial tumor hospital, Shijiazhuang, 050011, China

【机构】 河北医科大学第四医院暨河北省肿瘤医院妇产科；

【摘要】 目的:间皮素(mesothelin,MSLN)是由单克隆抗体CAK1在间皮细胞、间皮瘤和卵巢癌中识别的抗原。应用高通量的基因芯片技术发现MSLN在卵巢癌细胞有极高表达。近年研究显示MSLN和CA 125以特殊的方式结合,它们的表达和功能可能与患者的临床期别、人体的荷瘤量和病情进展有关。本研究从基因和蛋白两个水平上,结合临床病理探讨MSLN在正常卵巢皮质和卵巢上皮性肿瘤组织的表达状况及和CA125表达的相关性研究。方法:本研究标本取自河北医科大学第四医院妇产科2002年5月～2004年5月住院接受手术的患者或河北医科大学第四医院病理科2002年1 月～2004年4月存档的石蜡包埋组织。按照WHO要求进行病理分类。采用(1)半定量逆转录-聚合酶链反应(RT- PCR)方法检测MSLN的mRNA表达。(2)免疫组织化学 (SP)法检测MSLN和CA125蛋白的表达、定位及临床病理间的关系。所有结果应用CS2000第九版统计软件分析处理, 以P<0．05有统计意义。结果: MSLN和CA125蛋白表达在卵巢上皮性癌组织中显著高于卵巢良性上皮性肿瘤组织 (P<0．05),病理分级G2、G3级蛋白表达显著高于G1级(P <0．05),组织学分类中浆液性囊腺癌和宫内膜样癌蛋白表达显著高于粘液性囊腺癌(P<0．05),MSLN蛋白表达在年龄、腹水量及血清CA125的比较均无显著差异(P>0．05)。 CA125蛋白表达在病理分期Ⅲ、Ⅳ期的蛋白表达显著高于 I、Ⅱ期(P<0．05),MSLN蛋白表达在病理分期无显著性差异(P>0．05)。MSLN／β-actin在良性卵巢上皮性肿瘤和卵巢上皮性癌值分别为2．01±0．34和2．58±0．69,卵巢上皮性癌组织中MSLN／β-actin虽高于良性卵巢上皮性肿瘤,但经统计学分析,差异无显著性(P>0．05),但二者显著高于正常卵巢皮质的MSLN／β-actin表达1．12±0． 34(P<0．05)。卵巢癌MSLN／β-actin表达在年龄、分期、组织学类型、及腹水量差异均无显著性(P>0．05)。结论: MSLN和CA125的蛋白在正常卵巢皮质、卵巢良性上皮性肿瘤组织及卵巢上皮性癌组织中均有不同程度表达,蛋白表达量与上皮性卵巢细胞的良、恶性,分级及组织学类型密切相关。MSLNmRNA在正常卵巢皮质、良性卵巢上皮性肿瘤组织和卵巢上皮性癌组织中均有不同程度的表达,卵巢上皮性癌组织中MSLNmRNA虽高于良性卵巢上皮性肿瘤, 但经统计学分析,差异无显著性,但二者显著高于正常卵巢皮质的MSLNmRNA表达,且有显著性差异,MSLNmRNA 表达量与卵巢上皮性癌组织的年龄、分期、组织学类型及腹水量差异均无关。更多还原

【Abstract】 Objective: Mesothelin is a tumor antigen that was originally indentified by CAK-1 on mesothelial cells, mestheliomas and ovarian cancers. Using DNA microarrays find that mesothelin highly expresses in ovarian cells. Recently investigations find that CA125 binds to mesothelin in a specific manner, which might be connected with clinic grade, size of tumor in body and the state of an illness.To investigate the expression and correlation of mesothelin and CA125 in patients with normal ovarian and epithetlial ovarian cancer at protein level, to investigate the expression of meosthelin in patients with normal ovarian and epithelial ovarian tumors ar gene level. Methods: All samples were the admitted patients for operative treatment in our department According to the classification of tumor stage suggested by WHO. (1) Using RT-PCR methods to examine the expression of mesothelin gene.(2)Using immunohistochemistry to detect the expression, orientation and with clinic pathology of mesothelin and CA125. Results: The expression of mesothelin and CA125 in epithetlial ovarian cancer is significantly higher than that in benign ovarian tumor (P<0.05 ), the expression of pathology grade in G2,G3 is significantly higher than that in G1 ( P<0.05 ),the expression of histologic type in serous, endometrioid is significantly higher than that in mucinous (P<0.05 ).while in age, ascites and CA125 there is no difference ( P>0.05 ).The expression of CA125 stage in III 、IV is significantly higher than that in I 、II ( P<0.05 ). The expression of mesothelin mRNA was not siginificantly higher in malignant than that in benign tumor ( P>0.05 ). The expression level of mesothelin mRNA in benign epithetlial ovarian tumor and epithelial ovarian cancer is significantly higher than that in normal ovarian (P<0.05 ). In age, stage, histologic type and ascites the expression of them have no significant differences (P>0.05 ). Conclusion: The expression of mesothelin and CA125 is different in normal, benign tumor and epithetlial ovarian cancer at protein level. There is significant correlation between mesothelin, CA125 expression and benign, ovarian cancer, grade and histologic type of epithetlial ovarian cancer. Expression of mesothelin mRNA is different in normal ovarian, benign ovarian tumor and epithelial ovarian cancer. The expression level of mesothelin mRNAin benign epithetlial ovarian tumor and epithetlial ovarian cancer is significantly higher than that in normal ovarian (P<0.05 ).In age, stage, histologic type and ascites the ex- pression of them have no siginificant differentces( P>0.05 ).更多还原